YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Biocon

Biocon

BSE: 532523|NSE: BIOCON|ISIN: INE376G01013|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jan 13, 16:00
370.00
5.3 (1.45%)
VOLUME 85,911
LIVE
NSE
Jan 13, 15:59
370.25
5.4 (1.48%)
VOLUME 2,924,164
News on Biocon
Select Year: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Mylan-Biocon's breast cancer biosimilar gets ANVISA nod

2.43 pm | 29 Dec 2017 |  Source: PTI

Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan....

Buy Biocon, Havells, Maruti Suzuki: Sudarshan Sukhani 

1.24 pm | 27 Dec 2017 |  Source: CNBC-TV18

Sudarshan Sukhani of s2analytics.com advises buying Biocon, Havells and Maruti Suzuki....

Buy Biocon, Jet Airways: Sandeep Wagle 

3.56 pm | 19 Dec 2017 |  Source: CNBC-TV18

Sandeep Wagle of powermywealth.com suggests buying Biocon and Jet Airways....

Pharma Weekly Wrap: Pharma stocks rebound this week on buying interest

4.01 pm | 09 Dec 2017 |  Source: Moneycontrol.com

The hospital stocks remained stable despite the ongoing developments related to Delhi government cancelling license of Max Hospital Shalimar Bagh and ...

Biocon creates new subsidiary to unlock value of its biologics business

12.05 pm | 05 Dec 2017 |  Source: Moneycontrol.com

The biologics business consists biosimilars that include monoclonal antibodies and recombinant insulins and novel biologics...

Trastuzumab approval is a milestone: Biocon 

11.40 am | 04 Dec 2017 |  Source: CNBC-TV18

In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said Trastuzumab approval is a huge milestone. It has been under development for seve...

Biocon surges 14% after US FDA gives approval to biosimilar version of Herceptin

9.18 am | 04 Dec 2017 |  Source: Moneycontrol.com

Mylan and Biocon said that USFDA approved Mylan’s Ogivri, a biosimilar to Swiss biotech giant Roche's blockbuster cancer drug Herceptin, co-deve...

Buy, Sell, Hold: Infosys, Biocon and 1 major sector are on analysts’ radar today

8.48 am | 04 Dec 2017 |  Source: CNBC-TV18

Steel sector is being tracked by Bank of America Merrill Lynch on Monday....

News highlights of the day: Fitch Ratings cuts India FY18 growth forecast to 6.7%

7.16 am | 04 Dec 2017 |  Source: Moneycontrol.com

This blog will keep track of key global and local developments impacting business and markets through the day. Important local and global political de...

Pharma stocks remain subdued this week as investors book profit, Biocon stands tall

6.05 pm | 02 Dec 2017 |  Source: Moneycontrol.com

The BSE Healthcare index dropped 2.4 percent in the past week, while the BSE Sensex declined 1.3 percent...

US gives nod to Biocon-Mylan's biosimilar of cancer drug Herceptin, revenues expected from FY19 

3.12 pm | 02 Dec 2017 |  Source: Moneycontrol.com

Ogivri is the first FDA-approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the US...

Top 9 stocks which are looking attractive based on November expiry

10.41 am | 02 Dec 2017 |  Source: Moneycontrol.com

We continue to remain positive as long as 10,000 is sustained on the Nifty and the current correction can be utilised to enter into fresh long positio...

EMA communication with regards to Trastuzumab does not mean an approval: Biocon 

9.50 am | 01 Dec 2017 |  Source: CNBC-TV18

European Medicines Agency (EMA) has accepted the Trastuzumab application for review. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon ...

Biocon: EMA accepts Marketing Authorization Applications for Trastuzumab and Pegfilgrastim

8.50 am | 01 Dec 2017 |  Source: Moneycontrol.com

Mylan N. V. and Biocon announced that the European Medicines Agency (EMA) has accepted for review Mylan’s Marketing Authorization Applications (MAA)...

News Highlights of the Day: Search operation on in J&K's Baramulla after reports on terrorists

7.22 am | 01 Dec 2017 |  Source: Moneycontrol.com

This blog will keep track of key global and local developments impacting business and markets through the day. Important local and global political de...

Buy Biocon, sell Grasim Industries: Sandeep Wagle

3.06 pm | 28 Nov 2017 |  Source: CNBC-TV18

Sandeep Wagle of powermywealth.com is of the view that one can buy Biocon and sell Grasim Industries....

Biocon says cancer biosimilar Bevacizumab launch to boost India branded biz

5.55 pm | 23 Nov 2017 |  Source: Moneycontrol.com

The market size for Bevacizumab, both innovator product and biosimilars, in India is estimated at Rs 177 Crore (USD 27 million), according to IPSOS Ju...

Biocon introduces oncologic biosimilar KRABEVA in India

1.39 pm | 23 Nov 2017 |  Source: PTI

The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian...

News Live: Modi's government like Manmohan Desai's films, says Sitaram Yechury

7.06 am | 23 Nov 2017 |  Source: Moneycontrol.com

This blog will keep track of key global and local developments impacting business and markets through the day. Important local and global political de...

Biocon facility gets inspection closure report from USFDA

10.22 am | 20 Nov 2017 |  Source: PTI

"The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report in relation to the cGMP (current good manufacturing practic...

1 2 3 4 5 6 7 8
Quick Links for Biocon
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.